Dopamine D1 receptor and Dopamine D2 receptor (D1R and D2R)

Dopamine D1 and D2 receptors are two main subtypes of the dopamine receptor family, part of the G protein-coupled receptor (GPCR) superfamily[5][6][1][3][4]. Both are integral membrane proteins but differ in structure, signal transduction, brain distribution, pharmacology, and downstream effects. D1 receptors primarily couple to Gs proteins to activate adenylyl cyclase and increase cAMP, playing key roles in modulating excitatory neurotransmission, cognition, reward, and voluntary movement[3][2]. D2 receptors couple to Gi proteins, inhibit adenylyl cyclase, and decrease cAMP. D2 receptors also function as presynaptic autoreceptors, regulating dopamine release, and as postsynaptic receptors mediating inhibitory neurotransmission[5][2][6]. Both are central therapeutic targets in neuropsychiatric and neurodegenerative diseases, notably in Parkinson's disease and schizophrenia, where their pharmacological modulation has broad clinical utility. While often discussed jointly due to functional opposition and anatomical co-localization, D1 and D2 receptors are pharmacologically and genetically distinct targets, each with specific ligands, disease associations, and therapeutic implications.

Other names

Dopamine receptor D1 (DRD1)Dopamine receptor D2 (DRD2)D1 dopamine receptorD2 dopamine receptor

Agonists: Activate D1 or D2 receptors to stimulate/inhibit downstream signaling Antagonists: Block D1 or D2 receptors, reducing dopaminergic signaling Partial agonists: Provide submaximal receptor activation, stabilizing dopaminergic tone Allosteric modulators (investigational): Enhance or diminish responses to endogenous dopamine